Alexey Danilov, M.D., Ph.D.
- Hematology-Oncology
- Hematology & Hematopoietic Cell Transplantation
- Lymphoma
- Lymphoma Malignancies
- Marianne and Gerhard Pinkus Professor, Early Clinical Therapeutics
- Medical Director, Early Phase Therapeutics Program for the Systems Clinical Trials Office
- Co-Director, Toni Stephenson Lymphoma Center
- Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
"In oncology today, we are given great opportunities to make a lot of positive impact on the lives of our patients."
A board-certified clinician and talented researcher, Dr. Danilov is an internationally recognized physician, clinical trialist and translational investigator with expertise in chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. He is a Leukemia & Lymphoma Society Scholar and a Principal Investigator on multiple grants from the National Cancer Institute, Leukemia and Lymphoma Society, American Society of Hematology, and Lymphoma Research Foundation. He has initiated and led several dozen clinical trial protocols using novel targeted therapies and immunotherapies. Through partnerships with the National Cancer Institute and pharmaceutical industry and his leadership in the Lymphoma Committee at Southwest Oncology Group, Dr. Danilov participates in drug discovery on a global scale.
Dr. Danilov directs the City of Hope e ort in early phase clinical investigations through the National Cancer Institute Experimental Therapeutics Clinical Trials Network. As a Co-Director of the Toni Stephenson Lymphoma Center, Dr. Danilov leads clinical and translational e orts in lymphoma/leukemia at City of Hope.
An ideal fit for City of Hope, Dr. Danilov's lab concentrates on "bench to bedside" medicine, where preclinical findings lead to early phase clinical trials, ultimately translating into real treatments for real patients.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
2012, American Board of Internal Medicine, Hematology
2010, American Board of Internal Medicine, Medical Oncology
2007, American Board of Internal Medicine, Internal Medicine
2000, Ph.D., Yaroslavl Medical Academy, Russia
1997, M.D., summa cum laude, Yaroslavl Medical Academy, Russia
2007-2010, Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts
2004-2007, Medicine, Brown University School of Medicine, Providence, Rhode Island
2004-2005, Medicine, Brown University School of Medicine, Providence, RI
2020-Present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Associate Director, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
2020-Present, Translational Medicine Chair, SWOG Lymphoma
2014-2020, Assistant & Associate Professor of Medicine, Hematology - Oncology, OHSU, Portland, OR
2010-2014, Assistant Professor of Medicine, Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2001-2004, Research Scholar, Tufts University School of Medicine, Boston, MA
2000-2001, Instructor, Department of Medicine, Yaroslavl Medical Academy, Russia
1998-1999, Instructor, Department of Pathophysiology, Yaroslavl Medical Academy, Russia
Awards & Memberships
Awards
2023 Hope Colleague Award
2022 Abstract Achievement Awards, 64th ASH Annual Meeting (Gordon & Danilov)
2021 NCI R01 “Overcoming ibrutinib resistance in Mantle Cell Lymphoma”
2021 Leukemia & Lymphoma Society Translational Research Program Award
2021 Abstract Achievement Awards, 63rd ASH Annual Meeting (Thieme & Danilov)
2019, Abstract Achievement Award, 61st ASH Annual Meeting (Gordon & Danilov)
2018, Leukemia & Lymphoma Society Scholar in Clinical Research
2018, Abstract Achievement Award, 60th ASH Annual Meeting (Gordon & Danilov)
2017, Participant, SWOG Integrated Translational Science Center Workshop, Cold Spring Harbor Laboratories, NY
2017, Gebroe Family Lecture at the Lymphoma & Myeloma 2017, New York, NY
2017, Abstract Achievement Awards, 59th ASH Annual Meeting (Best & Danilov
Gordon & Danilov)
2016, Knight Cancer Institute Clinical Research Scholar
2016, Abstract Achievement Award, 58th ASH Annual Meeting (Paiva & Danilov)
2014, Lymphoma Research Foundation Clinical Investigator
2013, Best Abstract, Young Investigator/XV International Workshop on CLL, Köln/Germany
2013, Gazzaniga Family Prize for outstanding research at Dartmouth (Thesis Advisor to L.A.Humphries)
2012, Abstract Achievement Award, 54th ASH Annual Meeting (Humphries & Danilov)
2012, Participant, ASH Clinical Research Training Institute, La Jolla, CA2010, Excellence in Teaching Award, Medicine, Dartmouth-Hitchcock Medical Center
Memberships
2017, Member, SWOG CLL Study Group
2016, Member, SWOG Leukemia Working Group
2014, Member, SWOG Lymphoma Working Group
Publications
- Iyer P, Zhang B, Liu T, Jin M, Hart K, Zhang J, Siegert V, Remke M, Wang X, Yu L, Song J, Venkataraman G, Chan WC, Jia Z, Buchner M, Siddiqi T, Rosen ST, Danilov A, Wang L. MGA deletion leads to Richter's transformation by modulating mitochondrial OXPHOS. Sci Transl Med. 2024 Jul 31;16(758):eadg7915. doi: 10.1126/scitranslmed.adg7915. Epub 2024 Jul 31.PMID: 39083585
- Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, Brown JR. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. Haematologica. 2024 Oct 1;109(10):3379-3382. doi: 10.3324/haematol.2024.285043.
- Huynh T, Rodriguez-Rodriguez S, Danilov AV. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies. Mol Cancer Ther. 2024 May 2;23(5):619-626. doi: 10.1158/1535-7163.MCT-23-0520.
- Thieme E, Bruss N, Sun D, Dominguez EC, Coleman D, Liu T, Roleder C, Martinez M, Garcia-Mansfield K, Ball B, Pirrotte P, Wang L, Xia Z and Danilov AV. 2023. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Molecular Cancer. 22(1): 64.
- Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z and Danilov AV. 2023. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T cell responses in lymphoid neoplasia. Leukemia. 37 (6): 1324-1335.
- Kambhampati S, Shouse G and Danilov AV. 2023. Thinking “outside the germinal center”: re-educating T cells to combat follicular lymphoma. Blood Rev. doi: 10.1016/j.blre.2023.101099
- Shouse G*, Kaempf A*, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair S, Mian A, Fitzgerald L, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill B, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS and Danilov AV. 2023. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in diffuse large B cell lymphoma. Blood Adv. doi: 10.1182/bloodadvances.2022009309
- Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, Qin H, Muir A, Orand K, Borja I, Smith DL, Herrera AF, Spurgeon SE, Park B, Lewis LD, Hernandez-Ilizaliturri F, Xia Z and Danilov AV. 2023. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Cancer J. 13(1): 9.
- Thieme E*, Liu T*, Bruss N, Roleder C, Lam V, Wang X, Nechiporuk T, Shouse G, Danilova OV, Bottomly D, McWeeney SK, Tyner JW, Kurtz SE and Danilov AV. 2022. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death Dis. 13(3): 246.
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, …, Shadman M, Park B and Danilov AV. 2021. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 27(17): 4814-4824
- Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, Spurgeon S and Danilov AV. 2021. Entospletinib and obinutuzumab in patients with relapsed/refractory CLL and B-cell malignancies. Haematologica. 106 (7): 2022-2025.
- Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, Murray S, Berger A, Pennock ND, Lind EF and Danilov AV. 2021. Immunomodulatory effects of pevonedistat, a Nedd8-activating enzyme inhibitor, in CLL. Leukemia. 35(1): 156-168.
- Danilov AV, Persky DO. 2021. Incorporating acalabrutinib, a next-generation selective BTK inhibitor, into clinical practice for the treatment of hematologic malignancies. 2020. British Journal of Haematology. https://doi.org/10.1111/bjh.17184.
- Gordon MJ, Huang J, Chan RJ, Bhargava P and Danilov AV. 2021. Medical comorbidities in patients with chronic lymphocytic leukemia treated with idelalisib: analysis of two large randomized clinical trials. British J Haemtol. 192(4): 720-728.
- Danilov AV, Herbaux C, Walter H, Hillmen P, Rule S, Kio EA, Karlin L, Dyer MJ, Mitra S, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jurgensmeier JM and Fegan C. 2020. Phase 1b study of tirabrutinib alone or in combination with idelalisib or entospletinib in previously treated CLL. Clinical Cancer Research. 26 (12): 2810-2818.
- Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV and Tyner JW. 2020. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Nature Leukemia. doi: 10.1038/s41375-020-0764-6.
- Best SR, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A and Danilov AV. 2019. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances. 3(1): 51-62.
- Hashiguchi T, Bruss N, Best S, Lam V, Danilova OV, Paiva C, Wolf J, Gilbert E, Okada C, Kaur P, Drew L, Cidado J, Hurlin P and Danilov AV. 2019. Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma. Molecular Cancer Therapeutics. 18(9): 1520-1532.
- Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’Alessandro A, Culp-Hill R, d’Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK and Tyner JW. 2019. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discovery. 9 (7): 910-925.
- Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D and Danilov AV. 2018. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15): 3192-3200.
- Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Reister-Shulz A, Traer E, Abel M, …, Danilov AV, …, Druker BD. 2018. Functional genomic landscape of acute myeloid leukemia. Nature. doi: 10.1038/s41586-018-0623-z